{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T19:02:57Z","timestamp":1793300577039,"version":"4.5.0"},"reference-count":187,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Neurol"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1038\/s41582-024-00942-2","type":"journal-article","created":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T18:01:50Z","timestamp":1709316110000},"page":"232-244","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":202,"title":["Biomarker-based staging of Alzheimer disease: rationale and clinical applications"],"prefix":"10.1038","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7826-4781","authenticated-orcid":false,"given":"Joseph","family":"Therriault","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1680-1465","authenticated-orcid":false,"given":"Suzanne E.","family":"Schindler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5210-9230","authenticated-orcid":false,"given":"Gemma","family":"Salvad\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tharick A.","family":"Pascoal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9a Lessa","family":"Benedet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas J.","family":"Ashton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1422-4358","authenticated-orcid":false,"given":"Thomas K.","family":"Karikari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liana","family":"Apostolova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7379-2545","authenticated-orcid":false,"given":"Melissa E.","family":"Murray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0341-7445","authenticated-orcid":false,"given":"Inge","family":"Verberk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob W.","family":"Vogel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2581-8100","authenticated-orcid":false,"given":"Renaud","family":"La Joie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serge","family":"Gauthier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Teunissen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gil D.","family":"Rabinovici","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3930-4354","authenticated-orcid":false,"given":"Henrik","family":"Zetterberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7729-1702","authenticated-orcid":false,"given":"Randall J.","family":"Bateman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Scheltens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1890-4193","authenticated-orcid":false,"given":"Kaj","family":"Blennow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reisa","family":"Sperling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8467-7286","authenticated-orcid":false,"given":"Oskar","family":"Hansson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7916-622X","authenticated-orcid":false,"suffix":"Jr","given":"Clifford R.","family":"Jack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9116-1376","authenticated-orcid":false,"given":"Pedro","family":"Rosa-Neto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,3,1]]},"reference":[{"key":"942_CR1","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/S1474-4422(18)30403-4","volume":"18","author":"E Nichols","year":"2019","unstructured":"Nichols, E. et al. Global, regional, and national burden of Alzheimer\u2019s disease and other dementias, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 18, 88\u2013106 (2019).","journal-title":"Lancet Neurol."},{"key":"942_CR2","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","volume":"14","author":"CR Jack","year":"2018","unstructured":"Jack, C. R. et al. NIA-AA research framework: toward a biological definition of Alzheimer\u2019s disease. Alzheimers Dement. 14, 535\u2013562 (2018).","journal-title":"Alzheimers Dement."},{"key":"942_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jalz.2011.10.007","volume":"8","author":"BT Hyman","year":"2012","unstructured":"Hyman, B. T. et al. National Institute on Aging-Alzheimer\u2019s Association guidelines for the neuropathologic assessment of Alzheimer\u2019s disease. Alzheimers Dement. 8, 1\u201313 (2012).","journal-title":"Alzheimers Dement."},{"key":"942_CR4","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","volume":"7","author":"G McKhann","year":"2011","unstructured":"McKhann, G. et al. The diagnosis of dementia due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging- Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimers Dement. 7, 263\u2013269 (2011).","journal-title":"Alzheimers Dement."},{"key":"942_CR5","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1097\/NEN.0b013e31824b211b","volume":"71","author":"TG Beach","year":"2012","unstructured":"Beach, T. G., Monsell, S. E., Phillips, L. E. & Kukull, W. Accuracy of the clinical diagnosis of Alzheimer disease at National Institute on Aging Alzheimer Disease Centers, 2005-2010. J. Neuropathol. Exp. Neurol. 71, 266\u2013273 (2012).","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"942_CR6","doi-asserted-by":"publisher","first-page":"e975","DOI":"10.1212\/WNL.0000000000011416","volume":"96","author":"J Therriault","year":"2021","unstructured":"Therriault, J. et al. Frequency of biologically defined AD in relation to age, sex, APOE\u03b54, and cognitive impairment. Neurology 96, e975\u2013e985 (2021).","journal-title":"Neurology"},{"key":"942_CR7","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/S1474-4422(12)70291-0","volume":"12","author":"CR Jack","year":"2013","unstructured":"Jack, C. R. et al. Tracking pathophysiological processes in Alzheimer\u2019s disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol. 12, 207\u2013216 (2013).","journal-title":"Lancet Neurol."},{"key":"942_CR8","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1056\/NEJMoa1202753","volume":"367","author":"RJ Bateman","year":"2012","unstructured":"Bateman, R. J. et al. Clinical and biomarker changes in dominantly inherited Alzheimer\u2019s disease. N. Engl. J. Med. 367, 795\u2013804 (2012).","journal-title":"N. Engl. J. Med."},{"key":"942_CR9","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/S1474-4422(13)70044-9","volume":"12","author":"VL Villemagne","year":"2013","unstructured":"Villemagne, V. L. et al. Amyloid-\u03b2 deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer\u2019s disease: a prospective cohort study. Lancet Neurol. 12, 357\u2013367 (2013).","journal-title":"Lancet Neurol."},{"key":"942_CR10","doi-asserted-by":"publisher","first-page":"104450","DOI":"10.1016\/j.ebiom.2023.104450","volume":"88","author":"N Krishnadas","year":"2023","unstructured":"Krishnadas, N. et al. Rates of regional tau accumulation in ageing and across the Alzheimer\u2019s disease continuum: an AIBL 18F-MK6240 PET study. eBioMedicine 88, 104450 (2023).","journal-title":"eBioMedicine"},{"key":"942_CR11","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1001\/jama.1984.03340290051021","volume":"251","author":"JS Gonnella","year":"1984","unstructured":"Gonnella, J. S., Hornbrook, M. C. & Louis, D. Z. Staging of disease: a case-mix measurement. JAMA 251, 637\u2013644 (1984).","journal-title":"JAMA"},{"key":"942_CR12","doi-asserted-by":"publisher","first-page":"93","DOI":"10.3322\/caac.21388","volume":"67","author":"MB Amin","year":"2017","unstructured":"Amin, M. B. et al. The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more \u201cpersonalized\u201d approach to cancer staging. CA Cancer J. Clin. 67, 93\u201399 (2017).","journal-title":"CA Cancer J. Clin."},{"key":"942_CR13","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1001\/jama.2023.13239","volume":"330","author":"JR Sims","year":"2023","unstructured":"Sims, J. R. et al. Donanemab in early symptomatic Alzheimer disease the TRAILBLAZER-ALZ 2 randomized clinical trial. JAMA 330, 512\u2013527 (2023).","journal-title":"JAMA"},{"key":"942_CR14","unstructured":"Gauthier, S., Webster, C., Servaes, S., Morais, J. & Rosa\u2010Neto, P. World Alzheimer Report. Alzheimer\u2019s Disease International https:\/\/www.alzint.org\/u\/World-Alzheimer-Report-2022.pdf (2022)."},{"key":"942_CR15","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/S0140-6736(20)30367-6","volume":"396","author":"G Livingston","year":"2020","unstructured":"Livingston, G. et al. Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. Lancet 396, 413\u2013446 (2020).","journal-title":"Lancet"},{"key":"942_CR16","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1176\/ajp.139.9.1136","volume":"139","author":"B Reisberg","year":"1982","unstructured":"Reisberg, B., Ferris, S., De Leon, M. & Crook, T. The Global Deterioration Scale for assessment of primary degenerative dementia. Am. J. Psychiatry 139, 1136\u20131139 (1982).","journal-title":"Am. J. Psychiatry"},{"key":"942_CR17","unstructured":"FDA. Early Alzheimer\u2019s Disease: Developing Drugs for Treatment; Draft Guidance for Industry. FDA https:\/\/www.fda.gov\/media\/110903\/download (2018)."},{"key":"942_CR18","doi-asserted-by":"publisher","first-page":"2412","DOI":"10.1212\/WNL.43.11.2412-a","volume":"43","author":"JC Morris","year":"1993","unstructured":"Morris, J. C. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 43, 2412\u20132414 (1993).","journal-title":"Neurology"},{"key":"942_CR19","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1111\/j.1365-2796.2004.01388.x","volume":"256","author":"RC Petersen","year":"2004","unstructured":"Petersen, R. C. Mild cognitive impairment as a diagnostic entity. J. Intern. Med. 256, 183\u2013194 (2004).","journal-title":"J. Intern. Med."},{"key":"942_CR20","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1002\/ana.26071","volume":"89","author":"RC Petersen","year":"2021","unstructured":"Petersen, R. C. et al. NIA-AA Alzheimer\u2019s disease framework: clinical characterization of stages. Ann. Neurol. 89, 1145\u20131156 (2021).","journal-title":"Ann. Neurol."},{"key":"942_CR21","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1212\/01.wnl.0000271090.28148.24","volume":"69","author":"JA Schneider","year":"2007","unstructured":"Schneider, J. A., Arvanitakis, Z., Bang, W. & Bennett, D. A. Mixed brain pathologies account for most dementia cases in community-dwelling older persons. Neurology 69, 2197\u20132204 (2007).","journal-title":"Neurology"},{"key":"942_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00401-011-0910-3","volume":"123","author":"TJ Montine","year":"2012","unstructured":"Montine, T. J. et al. National Institute on Aging\u2013Alzheimer\u2019s Association guidelines for the neuropathologic assessment of Alzheimer\u2019s disease: a practical approach. Acta Neuropathol. 123, 1\u201311 (2012).","journal-title":"Acta Neuropathol."},{"key":"942_CR23","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1212\/WNL.58.12.1791","volume":"58","author":"DR Thal","year":"2002","unstructured":"Thal, D. R., R\u00fcb, U., Orantes, M. & Braak, H. Phases of AB-deposition in the human brain and its relevance for the development of AD. Neurology 58, 1791\u20131800 (2002).","journal-title":"Neurology"},{"key":"942_CR24","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1007\/s00401-006-0127-z","volume":"112","author":"H Braak","year":"2006","unstructured":"Braak, H., Alafuzoff, I., Arzberger, T., Kretzschmar, H. & Tredici, K. Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol. 112, 389\u2013404 (2006).","journal-title":"Acta Neuropathol."},{"key":"942_CR25","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/0197-4580(95)00021-6","volume":"16","author":"H Braak","year":"1995","unstructured":"Braak, H. & Braak, E. Staging of Alzheimer\u2019s disease-related neurofibrillary changes. Neurobiol. Aging 16, 271\u2013278 (1995).","journal-title":"Neurobiol. Aging"},{"key":"942_CR26","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1212\/WNL.41.4.479","volume":"41","author":"SS Mirra","year":"1991","unstructured":"Mirra, S. S. et al. The consortium to establish a registry for Alzheimer\u2019s disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer\u2019s disease. Neurology 41, 479\u2013486 (1991).","journal-title":"Neurology"},{"key":"942_CR27","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.jalz.2015.07.492","volume":"12","author":"TJ Montine","year":"2016","unstructured":"Montine, T. J. et al. Multisite assessment of NIA-AA guidelines for the neuropathologic evaluation of Alzheimer\u2019s disease. Alzheimers Dement. 12, 164\u2013169 (2016).","journal-title":"Alzheimers Dement."},{"key":"942_CR28","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.1001\/jama.2015.4668","volume":"313","author":"WJ Jansen","year":"2015","unstructured":"Jansen, W. J. et al. Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis. JAMA 313, 1924\u20131938 (2015).","journal-title":"JAMA"},{"key":"942_CR29","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1212\/WNL.0000000000002923","volume":"87","author":"CR Jack","year":"2016","unstructured":"Jack, C. R. et al. A\/T\/N: an unbiased descriptive classification scheme for Alzheimer disease biomarkers. Neurology 87, 539\u2013547 (2016).","journal-title":"Neurology"},{"key":"942_CR30","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1212\/WNL.0000000000007583","volume":"92","author":"DS Knopman","year":"2019","unstructured":"Knopman, D. S., Petersen, R. C. & Jack, C. R. A brief history of \u201cAlzheimer disease\u201d: multiple meanings separated by a common name. Neurology 92, 1053\u20131059 (2019).","journal-title":"Neurology"},{"key":"942_CR31","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1212\/WNL.55.3.370","volume":"55","author":"FA Schmitt","year":"2000","unstructured":"Schmitt, F. A. et al. \"Preclinical\u201d AD revisited: neuropathology of cognitively normal older adults. Neurology 55, 370\u2013376 (2000).","journal-title":"Neurology"},{"key":"942_CR32","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1093\/jnen\/62.11.1087","volume":"62","author":"DS Knopman","year":"2003","unstructured":"Knopman, D. S. et al. Neuropathology of cognitively normal elderly. J. Neuropathol. Exp. Neurol. 62, 1087\u20131095 (2003).","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"942_CR33","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1001\/archneur.63.5.665","volume":"63","author":"RC Petersen","year":"2006","unstructured":"Petersen, R. C. et al. Neuropathologic features of amnestic mild cognitive impairment. Arch. Neurol. 63, 655\u2013672 (2006).","journal-title":"Arch. Neurol."},{"key":"942_CR34","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1002\/ana.21706","volume":"66","author":"JA Schneider","year":"2009","unstructured":"Schneider, J. A., Arvanitakis, Z., Leurgans, S. E. & Bennett, D. A. The neuropathology of probable Alzheimer disease and mild cognitive impairment. Ann. Neurol. 66, 200\u2013208 (2009).","journal-title":"Ann. Neurol."},{"key":"942_CR35","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1093\/brain\/awz019","volume":"142","author":"BA Gordon","year":"2019","unstructured":"Gordon, B. A. et al. Tau PET in autosomal dominant Alzheimer\u2019s disease: relationship with cognition, dementia and other biomarkers. Brain 142, 1063\u20131076 (2019).","journal-title":"Brain"},{"key":"942_CR36","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1001\/jamaneurol.2021.5216","volume":"79","author":"WJ Jansen","year":"2022","unstructured":"Jansen, W. J. et al. Prevalence estimates of amyloid abnormality across the Alzheimer disease clinical spectrum. JAMA Neurol. 79, 228\u2013243 (2022).","journal-title":"JAMA Neurol."},{"key":"942_CR37","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1001\/jamaneurol.2019.1971","volume":"76","author":"CR Jack","year":"2019","unstructured":"Jack, C. R. et al. Prevalence of biologically vs clinically defined Alzheimer spectrum entities using the National Institute on Aging-Alzheimer\u2019s Association Research Framework. JAMA Neurol. 76, 1174\u20131183 (2019).","journal-title":"JAMA Neurol."},{"key":"942_CR38","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/S1474-4422(17)30077-7","volume":"16","author":"CR Jack","year":"2017","unstructured":"Jack, C. R. et al. Age-specific and sex-specific prevalence of cerebral \u03b2-amyloidosis, tauopathy, and neurodegeneration in cognitively unimpaired individuals aged 50\u201395 years: a cross-sectional study. Lancet Neurol. 16, 435\u2013444 (2017).","journal-title":"Lancet Neurol."},{"key":"942_CR39","doi-asserted-by":"publisher","first-page":"E1295","DOI":"10.1212\/WNL.0000000000006277","volume":"91","author":"E McDade","year":"2018","unstructured":"McDade, E. et al. Longitudinal cognitive and biomarker changes in dominantly inherited Alzheimer disease. Neurology 91, E1295\u2013E1306 (2018).","journal-title":"Neurology"},{"key":"942_CR40","doi-asserted-by":"publisher","first-page":"e479","DOI":"10.1016\/S2666-7568(21)00140-9","volume":"2","author":"CS Liang","year":"2021","unstructured":"Liang, C. S. et al. Mortality rates in Alzheimer\u2019s disease and non-Alzheimer\u2019s dementias: a systematic review and meta-analysis. Lancet Healthy Longev. 2, e479\u2013e488 (2021).","journal-title":"Lancet Healthy Longev."},{"key":"942_CR41","doi-asserted-by":"publisher","first-page":"3594","DOI":"10.1093\/brain\/awac181","volume":"145","author":"JC Morris","year":"2022","unstructured":"Morris, J. C. et al. Autosomal dominant and sporadic late onset Alzheimer\u2019s disease share a common in vivo pathophysiology. Brain 145, 3594\u20133607 (2022).","journal-title":"Brain"},{"key":"942_CR42","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.jalz.2011.03.003","volume":"7","author":"RA Sperling","year":"2011","unstructured":"Sperling, R. A. et al. Toward defining the preclinical stages of Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimers Dement. 7, 280\u2013292 (2011).","journal-title":"Alzheimers Dement."},{"key":"942_CR43","doi-asserted-by":"publisher","first-page":"2381","DOI":"10.1038\/s41591-022-02049-x","volume":"28","author":"R Ossenkoppele","year":"2022","unstructured":"Ossenkoppele, R. et al. Amyloid and tau PET-positive cognitively unimpaired individuals are at high risk for future cognitive decline. Nat. Med. 28, 2381\u20132387 (2022).","journal-title":"Nat. Med."},{"key":"942_CR44","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1001\/jamaneurol.2022.2379","volume":"79","author":"C Strikwerda-Brown","year":"2022","unstructured":"Strikwerda-Brown, C. et al. Association of elevated amyloid and tau positron emission tomography signal with near-term development of Alzheimer disease symptoms in older adults without cognitive impairment. JAMA Neurol. 79, 975\u2013985 (2022).","journal-title":"JAMA Neurol."},{"key":"942_CR45","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1002\/ana.25333","volume":"84","author":"D Bergeron","year":"2018","unstructured":"Bergeron, D. et al. Prevalence of amyloid-\u03b2 pathology in distinct variants of primary progressive aphasia. Ann. Neurol. 84, 729\u2013740 (2018).","journal-title":"Ann. Neurol."},{"key":"942_CR46","doi-asserted-by":"publisher","first-page":"1964","DOI":"10.1038\/s41591-023-02449-7","volume":"29","author":"C Quadalti","year":"2023","unstructured":"Quadalti, C. et al. Clinical effects of Lewy body pathology in cognitively impaired individuals. Nat. Med. 29, 1964\u20131970 (2023).","journal-title":"Nat. Med."},{"key":"942_CR47","doi-asserted-by":"publisher","first-page":"1971","DOI":"10.1038\/s41591-023-02450-0","volume":"29","author":"S Palmqvist","year":"2023","unstructured":"Palmqvist, S. et al. Cognitive effects of Lewy body pathology in clinically unimpaired individuals. Nat. Med. 29, 1971\u20131978 (2023).","journal-title":"Nat. Med."},{"key":"942_CR48","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1038\/s41591-021-01382-x","volume":"27","author":"O Hansson","year":"2021","unstructured":"Hansson, O. Biomarkers for neurodegenerative diseases. Nat. Med. 27, 954\u2013963 (2021).","journal-title":"Nat. Med."},{"key":"942_CR49","doi-asserted-by":"publisher","first-page":"2547","DOI":"10.1038\/s41591-022-02075-9","volume":"28","author":"K Horie","year":"2022","unstructured":"Horie, K. et al. CSF tau microtubule-binding region identifies pathological changes in primary tauopathies. Nat. Med. 28, 2547\u20132554 (2022).","journal-title":"Nat. Med."},{"key":"942_CR50","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/s41582-020-0348-0","volume":"16","author":"NJ Ashton","year":"2020","unstructured":"Ashton, N. J. et al. An update on blood-based biomarkers for non-Alzheimer neurodegenerative disorders. Nat. Rev. Neurol. 16, 265\u2013284 (2020).","journal-title":"Nat. Rev. Neurol."},{"key":"942_CR51","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1016\/S0140-6736(20)32205-4","volume":"397","author":"P Scheltens","year":"2021","unstructured":"Scheltens, P. et al. Alzheimer\u2019s disease. Lancet 397, 1577\u20131590 (2021).","journal-title":"Lancet"},{"key":"942_CR52","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-29047-4","volume":"13","author":"D Jones","year":"2022","unstructured":"Jones, D. et al. A computational model of neurodegeneration in Alzheimer\u2019s disease. Nat. Commun. 13, 1643 (2022).","journal-title":"Nat. Commun."},{"key":"942_CR53","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.bbi.2023.07.023","volume":"113","author":"LJ De Picker","year":"2023","unstructured":"De Picker, L. J. et al. TSPO PET brain inflammation imaging: a transdiagnostic systematic review and meta-analysis of 156 case-control studies. Brain Behav. Immun. 113, 415\u2013431 (2023).","journal-title":"Brain Behav. Immun."},{"key":"942_CR54","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1001\/jamaneurol.2019.2214","volume":"76","author":"N Mattsson","year":"2019","unstructured":"Mattsson, N., Palmqvist, S., Stomrud, E., Vogel, J. & Hansson, O. Staging \u03b2-amyloid pathology with amyloid positron emission tomography. JAMA Neurol. 76, 1319\u20131329 (2019).","journal-title":"JAMA Neurol."},{"key":"942_CR55","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1038\/s41467-017-01150-x","volume":"8","author":"S Palmqvist","year":"2017","unstructured":"Palmqvist, S. et al. Earliest accumulation of \u03b2-amyloid occurs within the default-mode network and concurrently affects brain connectivity. Nat. Commun. 8, 1214\u20131226 (2017).","journal-title":"Nat. Commun."},{"key":"942_CR56","doi-asserted-by":"publisher","first-page":"166","DOI":"10.2967\/jnumed.119.235879","volume":"61","author":"E Fantoni","year":"2020","unstructured":"Fantoni, E., Collij, L., Alves, I. L., Buckley, C. & Farrar, G. The spatial-temporal ordering of amyloid pathology and opportunities for PET imaging. J. Nucl. Med. 61, 166\u2013171 (2020).","journal-title":"J. Nucl. Med."},{"key":"942_CR57","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1212\/WNL.0000000000004643","volume":"89","author":"MJ Grothe","year":"2017","unstructured":"Grothe, M. J. et al. In vivo staging of regional amyloid deposition. Neurology 89, 2031\u20132038 (2017).","journal-title":"Neurology"},{"key":"942_CR58","doi-asserted-by":"publisher","first-page":"4219","DOI":"10.1002\/hbm.25121","volume":"41","author":"I Jelistratova","year":"2020","unstructured":"Jelistratova, I., Teipel, S. J. & Grothe, M. J. Longitudinal validity of PET-based staging of regional amyloid deposition. Hum. Brain Mapp. 41, 4219\u20134231 (2020).","journal-title":"Hum. Brain Mapp."},{"key":"942_CR59","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1186\/s13195-021-00918-0","volume":"13","author":"F Levin","year":"2021","unstructured":"Levin, F. et al. In vivo staging of regional amyloid progression in healthy middle-aged to older people at risk of Alzheimer\u2019s disease. Alzheimers Res. Ther. 13, 178 (2021).","journal-title":"Alzheimers Res. Ther."},{"key":"942_CR60","doi-asserted-by":"publisher","first-page":"e1538","DOI":"10.1212\/WNL.0000000000010256","volume":"95","author":"LE Collij","year":"2020","unstructured":"Collij, L. E. et al. Multitracer model for staging cortical amyloid deposition using PET imaging. Neurology 95, e1538\u2013e1553 (2020).","journal-title":"Neurology"},{"key":"942_CR61","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1001\/jamaneurol.2022.2442","volume":"79","author":"H Ozlen","year":"2022","unstructured":"Ozlen, H. et al. Spatial extent of amyloid-\u03b2 levels and associations with tau-PET and cognition. JAMA Neurol. 79, 1025\u20131035 (2022).","journal-title":"JAMA Neurol."},{"key":"942_CR62","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1007\/s00259-020-05174-2","volume":"48","author":"LE Collij","year":"2021","unstructured":"Collij, L. E. et al. Visual assessment of [18F]flutemetamol PET images can detect early amyloid pathology and grade its extent. Eur. J. Nucl. Med. Mol. Imaging 48, 2169\u20132182 (2021).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"942_CR63","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1038\/s43587-022-00204-0","volume":"2","author":"J Therriault","year":"2022","unstructured":"Therriault, J. et al. Biomarker modeling of Alzheimer\u2019s disease using PET-based Braak staging. Nat. Aging 2, 526\u2013535 (2022).","journal-title":"Nat. Aging"},{"key":"942_CR64","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1212\/WNL.0b013e3182840bbe","volume":"80","author":"CR Jack","year":"2013","unstructured":"Jack, C. R. et al. Brain \u03b2-amyloid load approaches a plateau. Neurology 80, 890\u2013896 (2013).","journal-title":"Neurology"},{"key":"942_CR65","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jalz.2014.07.003","volume":"11","author":"WE Klunk","year":"2015","unstructured":"Klunk, W. E. et al. The Centiloid project: standardizing quantitative amyloid plaque estimation by PET. Alzheimers Dement. 11, 1\u201315.e1-4 (2015).","journal-title":"Alzheimers Dement."},{"key":"942_CR66","doi-asserted-by":"publisher","first-page":"3508","DOI":"10.1007\/s00259-022-05784-y","volume":"49","author":"HG Pemberton","year":"2022","unstructured":"Pemberton, H. G. et al. Quantification of amyloid PET for future clinical use: a state-of-the-art review. Eur. J. Nucl. Med. Mol. Imaging 49, 3508\u20133528 (2022).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"942_CR67","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.jalz.2018.09.001","volume":"15","author":"R La Joie","year":"2019","unstructured":"La Joie, R. et al. Multisite study of the relationships between antemortem [11C]PIB-PET Centiloid values and postmortem measures of Alzheimer\u2019s disease neuropathology. Alzheimers Dement. 15, 205\u2013216 (2019).","journal-title":"Alzheimers Dement."},{"key":"942_CR68","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.jalz.2016.08.005","volume":"13","author":"CR Jack","year":"2017","unstructured":"Jack, C. R. et al. Defining imaging biomarker cut points for brain aging and Alzheimer\u2019s disease. Alzheimers Dement. 13, 205\u2013216 (2017).","journal-title":"Alzheimers Dement."},{"key":"942_CR69","volume":"15","author":"J Therriault","year":"2023","unstructured":"Therriault, J. et al. Amyloid beta plaque accumulation with longitudinal [18F]AZD4694 PET. Alzheimers Dement. 15, e12391 (2023).","journal-title":"Alzheimers Dement."},{"key":"942_CR70","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/j.neuron.2016.01.028","volume":"89","author":"M Sch\u00f6ll","year":"2016","unstructured":"Sch\u00f6ll, M. et al. PET imaging of tau deposition in the aging human brain. Neuron 89, 971\u2013982 (2016).","journal-title":"Neuron"},{"key":"942_CR71","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1002\/ana.24546","volume":"79","author":"KA Johnson","year":"2016","unstructured":"Johnson, K. A. et al. Tau positron emission tomographic imaging in aging and early Alzheimer disease. Ann. Neurol. 79, 110\u2013119 (2016).","journal-title":"Ann. Neurol."},{"key":"942_CR72","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1093\/brain\/awx320","volume":"141","author":"VJ Lowe","year":"2018","unstructured":"Lowe, V. J. et al. Widespread brain tau and its association with ageing, Braak stage and Alzheimer\u2019s dementia. Brain 141, 271\u2013287 (2018).","journal-title":"Brain"},{"key":"942_CR73","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.2967\/jnumed.122.265200","volume":"64","author":"AC Macedo","year":"2023","unstructured":"Macedo, A. C. et al. The use of tau PET to stage Alzheimer disease according to the Braak staging framework. J. Nucl. Med. 64, 1171\u20131178 (2023).","journal-title":"J. Nucl. Med."},{"key":"942_CR74","doi-asserted-by":"publisher","unstructured":"St-Onge, F. et al. Tau accumulation and its spatial progression across the Alzheimer\u2019s disease spectrum. Preprint at\u00a0medRxiv https:\/\/doi.org\/10.1101\/2023.06.02.23290880 (2023).","DOI":"10.1101\/2023.06.02.23290880"},{"key":"942_CR75","doi-asserted-by":"publisher","first-page":"2818","DOI":"10.1093\/brain\/awaa180","volume":"143","author":"TA Pascoal","year":"2020","unstructured":"Pascoal, T. A. et al. 18F-MK-6240 PET for early and late detection of neurofibrillary tangles. Brain 143, 2818\u20132830 (2020).","journal-title":"Brain"},{"key":"942_CR76","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1001\/jamaneurol.2023.2560","volume":"80","author":"A Costoya-S\u00e1nchez","year":"2023","unstructured":"Costoya-S\u00e1nchez, A. et al. Increased medial temporal tau positron emission tomography uptake in the absence of amyloid-\u03b2 positivity. JAMA Neurol. 80, 1051\u20131061 (2023).","journal-title":"JAMA Neurol."},{"key":"942_CR77","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1007\/s00401-014-1349-0","volume":"128","author":"JF Crary","year":"2014","unstructured":"Crary, J. F. et al. Primary age-related tauopathy (PART): a common pathology associated with human aging. Acta Neuropathol. 128, 755\u2013766 (2014).","journal-title":"Acta Neuropathol."},{"key":"942_CR78","doi-asserted-by":"publisher","first-page":"3192","DOI":"10.1093\/brain\/awad135","volume":"146","author":"A Wuestefeld","year":"2023","unstructured":"Wuestefeld, A. et al. Age-related and amyloid-beta-independent tau deposition and its downstream effects. Brain 146, 3192\u20133205 (2023).","journal-title":"Brain"},{"key":"942_CR79","doi-asserted-by":"publisher","first-page":"3106","DOI":"10.1093\/brain\/awad210","volume":"146","author":"J Therriault","year":"2023","unstructured":"Therriault, J. & Grothe, M. J. Towards in vivo PET imaging of primary age-related tauopathy. Brain 146, 3106\u20133109 (2023).","journal-title":"Brain"},{"key":"942_CR80","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1038\/s41583-018-0067-3","volume":"19","author":"W Jagust","year":"2018","unstructured":"Jagust, W. Imaging the evolution and pathophysiology of Alzheimer disease. Nat. Rev. Neurosci. 19, 687\u2013700 (2018).","journal-title":"Nat. Rev. Neurosci."},{"key":"942_CR81","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1002\/ana.10161","volume":"51","author":"KP Riley","year":"2002","unstructured":"Riley, K. P., Snowdon, D. A. & Markesbery, W. R. Alzheimer\u2019s neurofibrillary pathology and the spectrum of cognitive function: findings from the Nun Study. Ann. Neurol. 51, 567\u2013577 (2002).","journal-title":"Ann. Neurol."},{"key":"942_CR82","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1212\/01.wnl.0000324924.91351.7d","volume":"71","author":"JL Whitwell","year":"2008","unstructured":"Whitwell, J. L. et al. MRI correlates of neurofibrillary tangle pathology at autopsy: a voxel-based morphometry study. Neurology 71, 743\u2013749 (2008).","journal-title":"Neurology"},{"key":"942_CR83","doi-asserted-by":"publisher","DOI":"10.14283\/jpad.2024.15","author":"AC Macedo","year":"2024","unstructured":"Macedo, A. C. et al. Clinical correlates of the PET-based Braak staging framework in Alzheimer\u2019s disease. J. Prev. Alzheimers Dis. https:\/\/doi.org\/10.14283\/jpad.2024.15 (2024).","journal-title":"J. Prev. Alzheimers Dis."},{"key":"942_CR84","doi-asserted-by":"publisher","first-page":"2497","DOI":"10.1002\/alz.12875","volume":"19","author":"R Smith","year":"2023","unstructured":"Smith, R. et al. Tau-PET is superior to phospho-tau when predicting cognitive decline in symptomatic AD patients. Alzheimers Dement. 19, 2497\u20132507 (2023).","journal-title":"Alzheimers Dement."},{"key":"942_CR85","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1001\/jamaneurol.2021.1858","volume":"78","author":"R Ossenkoppele","year":"2021","unstructured":"Ossenkoppele, R. et al. Accuracy of tau positron emission tomography as a prognostic marker in preclinical and prodromal Alzheimer disease. JAMA Neurol. 78, 961\u2013971 (2021).","journal-title":"JAMA Neurol."},{"key":"942_CR86","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1038\/s43587-023-00405-1","volume":"3","author":"L Montoliu-Gaya","year":"2023","unstructured":"Montoliu-Gaya, L. et al. Mass spectrometric simultaneous quantification of tau species in plasma shows differential associations with amyloid and tau pathologies. Nat. Aging 3, 661\u2013669 (2023).","journal-title":"Nat. Aging"},{"key":"942_CR87","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJMoa2100708","volume":"384","author":"MA Mintun","year":"2021","unstructured":"Mintun, M. A. et al. Donanemab in early Alzheimer\u2019s disease. N. Engl. J. Med. 384, 1691\u20131704 (2021).","journal-title":"N. Engl. J. Med."},{"key":"942_CR88","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1016\/j.molmed.2022.05.008","volume":"28","author":"J Therriault","year":"2022","unstructured":"Therriault, J. et al. Staging of Alzheimer\u2019s disease: past, present, and future perspectives. Trends Mol. Med. 28, 726\u2013741 (2022).","journal-title":"Trends Mol. Med."},{"key":"942_CR89","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.2967\/jnumed.120.258962","volume":"62","author":"A Whittington","year":"2021","unstructured":"Whittington, A. & Gunn, R. N. TauIQ: a canonical image based algorithm to quantify tau PET scans. J. Nucl. Med. 62, 1292\u20131300 (2021).","journal-title":"J. Nucl. Med."},{"key":"942_CR90","doi-asserted-by":"publisher","first-page":"3276","DOI":"10.1007\/s00259-023-06279-0","volume":"50","author":"A Jovalekic","year":"2023","unstructured":"Jovalekic, A. et al. Validation of quantitative assessment of florbetaben PET scans as an adjunct to the visual assessment across 15 software methods. Eur. J. Nucl. Med. Mol. Imaging 50, 3276\u20133289 (2023).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"942_CR91","doi-asserted-by":"publisher","unstructured":"Gebre, R. K. et al. Advancing Tau-PET quantification in Alzheimer\u2019s disease with machine learning: introducing THETA, a novel tau summary measure. Preprint at Res. Sq. https:\/\/doi.org\/10.21203\/rs.3.rs-3290598\/v1 (2023).","DOI":"10.21203\/rs.3.rs-3290598\/v1"},{"key":"942_CR92","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1186\/s13195-022-01117-1","volume":"14","author":"AL Brand","year":"2022","unstructured":"Brand, A. L. et al. The performance of plasma amyloid beta measurements in identifying amyloid plaques in Alzheimer\u2019s disease: a literature review. Alzheimers Res. Ther. 14, 195 (2022).","journal-title":"Alzheimers Res. Ther."},{"key":"942_CR93","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1002\/ana.24454","volume":"78","author":"BW Patterson","year":"2015","unstructured":"Patterson, B. W. et al. Age and amyloid effects on human central nervous system amyloid-beta kinetics. Ann. Neurol. 78, 439\u2013453 (2015).","journal-title":"Ann. Neurol."},{"key":"942_CR94","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1093\/brain\/aww015","volume":"139","author":"S Palmqvist","year":"2016","unstructured":"Palmqvist, S., Mattsson, N. & Hansson, O. Cerebrospinal fluid analysis detects cerebral amyloid-\u03b2 accumulation earlier than positron emission tomography. Brain 139, 1226\u20131236 (2016).","journal-title":"Brain"},{"key":"942_CR95","doi-asserted-by":"publisher","first-page":"E1647","DOI":"10.1212\/WNL.0000000000008081","volume":"93","author":"SE Schindler","year":"2019","unstructured":"Schindler, S. E. et al. High-precision plasma \u03b2-amyloid 42\/40 predicts current and future brain amyloidosis. Neurology 93, E1647\u2013E1659 (2019).","journal-title":"Neurology"},{"key":"942_CR96","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1038\/s41591-020-0781-z","volume":"26","author":"NR Barth\u00e9lemy","year":"2020","unstructured":"Barth\u00e9lemy, N. R. et al. A soluble phosphorylated tau signature links tau, amyloid and the evolution of stages of dominantly inherited Alzheimer\u2019s disease. Nat. Med. 26, 398\u2013407 (2020).","journal-title":"Nat. Med."},{"key":"942_CR97","first-page":"1797","volume":"28","author":"M Mil\u00e0-Alom\u00e0","year":"2022","unstructured":"Mil\u00e0-Alom\u00e0, M. et al. Plasma p-tau231 and p-tau217 as state markers of amyloid-\u03b2 pathology in preclinical Alzheimer\u2019s disease. Nat. Med. 28, 1797\u20131801 (2022).","journal-title":"Nat. Med."},{"key":"942_CR98","doi-asserted-by":"publisher","first-page":"2555","DOI":"10.1038\/s41591-022-02074-w","volume":"28","author":"NJ Ashton","year":"2022","unstructured":"Ashton, N. J. et al. Differential roles of A\u03b242\/40, p-tau231 and p-tau217 for Alzheimer\u2019s trial selection and disease monitoring. Nat. Med. 28, 2555\u20132562 (2022).","journal-title":"Nat. Med."},{"key":"942_CR99","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1001\/jamaneurol.2022.4485","volume":"80","author":"J Therriault","year":"2023","unstructured":"Therriault, J. et al. Association of phosphorylated tau biomarkers with amyloid positron emission tomography vs tau positron emission tomography. JAMA Neurol. 80, 188\u2013199 (2023).","journal-title":"JAMA Neurol."},{"key":"942_CR100","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.202217123","volume":"46","author":"G Salvad\u00f3","year":"2023","unstructured":"Salvad\u00f3, G. et al. Specific associations between plasma biomarkers and postmortem amyloid plaque and tau tangle loads. EMBO Mol. Med. 46, e17123 (2023).","journal-title":"EMBO Mol. Med."},{"key":"942_CR101","doi-asserted-by":"publisher","first-page":"103836","DOI":"10.1016\/j.ebiom.2022.103836","volume":"76","author":"NJ Ashton","year":"2022","unstructured":"Ashton, N. J. et al. Cerebrospinal fluid p-tau231 as an early indicator of emerging pathology in Alzheimer\u2019s disease. eBioMedicine 76, 103836 (2022).","journal-title":"eBioMedicine"},{"key":"942_CR102","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1186\/s13024-022-00578-0","volume":"17","author":"ME Murray","year":"2022","unstructured":"Murray, M. E. et al. Global neuropathologic severity of Alzheimer\u2019s disease and locus coeruleus vulnerability influences plasma phosphorylated tau levels. Mol. Neurodegener. 17, 85 (2022).","journal-title":"Mol. Neurodegener."},{"key":"942_CR103","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.202114022","volume":"13","author":"N Mattsson\u2010Carlgren","year":"2021","unstructured":"Mattsson\u2010Carlgren, N. et al. Soluble P\u2010tau217 reflects amyloid and tau pathology and mediates the association of amyloid with tau. EMBO Mol. Med. 13, e14022 (2021).","journal-title":"EMBO Mol. Med."},{"key":"942_CR104","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1001\/jama.2020.12134","volume":"324","author":"S Palmqvist","year":"2020","unstructured":"Palmqvist, S. et al. Discriminative accuracy of plasma phospho-tau217 for Alzheimer disease vs other neurodegenerative disorders. JAMA 324, 772\u2013781 (2020).","journal-title":"JAMA"},{"key":"942_CR105","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1001\/jamaneurol.2020.4201","volume":"78","author":"S Janelidze","year":"2021","unstructured":"Janelidze, S. et al. Associations of plasma phospho-tau217 levels with tau positron emission tomography in early Alzheimer disease. JAMA Neurol. 78, 149\u2013156 (2021).","journal-title":"JAMA Neurol."},{"key":"942_CR106","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.202012921","volume":"12","author":"M Su\u00e1rez\u2010Calvet","year":"2020","unstructured":"Su\u00e1rez\u2010Calvet, M. et al. Novel tau biomarkers phosphorylated at T181, T217 or T231 rise in the initial stages of the preclinical Alzheimer\u2019s continuum when only subtle changes in A\u03b2 pathology are detected. EMBO Mol. Med. 12, e12921 (2020).","journal-title":"EMBO Mol. Med."},{"key":"942_CR107","doi-asserted-by":"publisher","first-page":"fcad057","DOI":"10.1093\/braincomms\/fcad057","volume":"5","author":"EM Jonaitis","year":"2023","unstructured":"Jonaitis, E. M. et al. Plasma phosphorylated tau 217 in preclinical Alzheimer\u2019s disease. Brain Commun. 5, fcad057 (2023).","journal-title":"Brain Commun."},{"key":"942_CR108","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1001\/jamaneurol.2021.2293","volume":"78","author":"MM Mielke","year":"2021","unstructured":"Mielke, M. M. et al. Comparison of plasma phosphorylated tau species with amyloid and tau positron emission tomography, neurodegeneration, vascular pathology, and cognitive outcomes. JAMA Neurol. 78, 1108\u20131117 (2021).","journal-title":"JAMA Neurol."},{"key":"942_CR109","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.202114398","volume":"13","author":"R Ossenkoppele","year":"2021","unstructured":"Ossenkoppele, R. et al. Tau PET correlates with different Alzheimer\u2019s disease\u2010related features compared to CSF and plasma p\u2010tau biomarkers. EMBO Mol. Med. 13, e14398 (2021).","journal-title":"EMBO Mol. Med."},{"key":"942_CR110","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s13024-023-00689-2","volume":"19","author":"J Therriault","year":"2024","unstructured":"Therriault, J. et al. Comparison of immunoassay- with mass spectrometry-derived p-tau quantification for the detection of Alzheimer\u2019s disease pathology. Mol. Neurodegener. 19, 2 (2024).","journal-title":"Mol. Neurodegener."},{"key":"942_CR111","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1038\/s43587-023-00380-7","volume":"3","author":"NR Barth\u00e9lemy","year":"2023","unstructured":"Barth\u00e9lemy, N. R. et al. CSF tau phosphorylation occupancies at T217 and T205 represent improved biomarkers of amyloid and tau pathology in Alzheimer\u2019s disease. Nat. Aging 3, 391\u2013401 (2023).","journal-title":"Nat. Aging"},{"key":"942_CR112","unstructured":"Salvad\u00f3, G., Horie, K., Barth\u00e9lemy, N. R. & Vogel, J. W. Novel CSF tau biomarkers can be used for disease staging of sporadic Alzheimer\u2019s disease. Nat. Aging\u00a0(in the press)."},{"key":"942_CR113","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1007\/s00401-023-02659-w","volume":"147","author":"J Lantero-Rodr\u00edguez","year":"2024","unstructured":"Lantero-Rodr\u00edguez, J. et al. CSF p-tau205: a biomarker of tau pathology in Alzheimer\u2019s disease. Acta Neuropathol. 147, 12 (2024).","journal-title":"Acta Neuropathol."},{"key":"942_CR114","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1093\/brain\/awaa373","volume":"144","author":"K Horie","year":"2021","unstructured":"Horie, K., Barth\u00e9lemy, N. R., Sato, C. & Bateman, R. J. CSF tau microtubule binding region identifies tau tangle and clinical stages of Alzheimer\u2019s disease. Brain 144, 515\u2013527 (2021).","journal-title":"Brain"},{"key":"942_CR115","doi-asserted-by":"publisher","first-page":"1954","DOI":"10.1038\/s41591-023-02443-z","volume":"29","author":"K Horie","year":"2023","unstructured":"Horie, K. et al. CSF MTBR-tau243 is a specific biomarker of tau pathology in Alzheimer\u2019s disease. Nat. Med. 29, 1954\u20131963 (2023).","journal-title":"Nat. Med."},{"key":"942_CR116","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1186\/s13195-022-01142-0","volume":"14","author":"J Simr\u00e9n","year":"2022","unstructured":"Simr\u00e9n, J. et al. CSF tau368\/total-tau ratio reflects cognitive performance and neocortical tau better compared to p-tau181 and p-tau217 in cognitively impaired individuals. Alzheimers Res. Ther. 14, 192 (2022).","journal-title":"Alzheimers Res. Ther."},{"key":"942_CR117","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1093\/brain\/awz346","volume":"143","author":"K Blennow","year":"2020","unstructured":"Blennow, K. et al. Cerebrospinal fluid tau fragment correlates with tau PET: a candidate biomarker for tangle pathology. Brain 143, 650\u2013660 (2020).","journal-title":"Brain"},{"key":"942_CR118","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.202115098","volume":"13","author":"J Lantero\u2010Rodriguez","year":"2021","unstructured":"Lantero\u2010Rodriguez, J. et al. P\u2010tau235: a novel biomarker for staging preclinical Alzheimer\u2019s disease. EMBO Mol. Med. 13, e15098 (2021).","journal-title":"EMBO Mol. Med."},{"key":"942_CR119","doi-asserted-by":"publisher","first-page":"5343","DOI":"10.1002\/alz.13119","volume":"19","author":"J Lantero-Rodriguez","year":"2023","unstructured":"Lantero-Rodriguez, J. et al. Plasma and CSF concentrations of N-terminal tau fragments associate with in vivo neurofibrillary tangle burden. Alzheimers Dement. 19, 5343\u20135354 (2023).","journal-title":"Alzheimers Dement."},{"key":"942_CR120","doi-asserted-by":"publisher","first-page":"2834","DOI":"10.1093\/brain\/awab481","volume":"145","author":"A Snellman","year":"2022","unstructured":"Snellman, A. et al. N-Terminal and mid-region tau fragments as fluid biomarkers in neurological diseases. Brain 145, 2834\u20132848 (2022).","journal-title":"Brain"},{"key":"942_CR121","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-19543-w","volume":"11","author":"JP Chhatwal","year":"2020","unstructured":"Chhatwal, J. P. et al. Plasma N-terminal tau fragment levels predict future cognitive decline and neurodegeneration in healthy elderly individuals. Nat. Commun. 11, 6024 (2020).","journal-title":"Nat. Commun."},{"key":"942_CR122","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1002\/ana.25885","volume":"88","author":"D Mengel","year":"2020","unstructured":"Mengel, D. et al. Plasma NT1 Tau is a specific and early marker of Alzheimer\u2019s disease. Ann. Neurol. 88, 878\u2013892 (2020).","journal-title":"Ann. Neurol."},{"key":"942_CR123","doi-asserted-by":"publisher","first-page":"eaaz2387","DOI":"10.1126\/sciadv.aaz2387","volume":"6","author":"N Mattsson-Carlgren","year":"2020","unstructured":"Mattsson-Carlgren, N. et al. A\u03b2 deposition is associated with increases in soluble and phosphorylated tau that precede a positive Tau PET in Alzheimer\u2019s disease. Sci. Adv. 6, eaaz2387 (2020).","journal-title":"Sci. Adv."},{"key":"942_CR124","doi-asserted-by":"publisher","first-page":"23645","DOI":"10.1074\/jbc.M703269200","volume":"282","author":"DP Hanger","year":"2007","unstructured":"Hanger, D. P. et al. Novel phosphorylation sites in tau from Alzheimer brain support a role for casein kinase 1 in disease pathogenesis. J. Biol. Chem. 282, 23645\u201323654 (2007).","journal-title":"J. Biol. Chem."},{"key":"942_CR125","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1007\/s004010100423","volume":"103","author":"JC Augustinack","year":"2002","unstructured":"Augustinack, J. C., Schneider, A., Mandelkow, E. M. & Hyman, B. T. Specific tau phosphorylation sites correlate with severity of neuronal cytopathology in Alzheimer\u2019s disease. Acta Neuropathol. 103, 26\u201335 (2002).","journal-title":"Acta Neuropathol."},{"key":"942_CR126","doi-asserted-by":"publisher","first-page":"2029","DOI":"10.1093\/brain\/awad042","volume":"146","author":"CR Jack","year":"2023","unstructured":"Jack, C. R. et al. Predicting amyloid PET and tau PET stages with plasma biomarkers. Brain 146, 2029\u20132044 (2023).","journal-title":"Brain"},{"key":"942_CR127","doi-asserted-by":"publisher","first-page":"e1681","DOI":"10.1212\/WNL.0000000000012727","volume":"97","author":"A Leuzy","year":"2021","unstructured":"Leuzy, A. et al. Comparing the clinical utility and diagnostic performance of CSF p-tau181, p-tau217, and p-tau231 assays. Neurology 97, e1681\u2013e1694 (2021).","journal-title":"Neurology"},{"key":"942_CR128","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1001\/jamaneurol.2021.3180","volume":"78","author":"S Janelidze","year":"2021","unstructured":"Janelidze, S. et al. Head-to-head comparison of 8 plasma amyloid-\u03b2 42\/40 assays in Alzheimer disease. JAMA Neurol. 78, 1375\u20131382 (2021).","journal-title":"JAMA Neurol."},{"key":"942_CR129","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1093\/brain\/awac333","volume":"146","author":"S Janelidze","year":"2023","unstructured":"Janelidze, S. et al. Head-to-head comparison of 10 plasma phospho-tau assays in prodromal Alzheimer\u2019s disease. Brain 146, 1592\u20131601 (2023).","journal-title":"Brain"},{"key":"942_CR130","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1002\/alz.12841","volume":"19","author":"NJ Ashton","year":"2023","unstructured":"Ashton, N. J. et al. Plasma and CSF biomarkers in a memory clinic: head-to-head comparison of phosphorylated tau immunoassays. Alzheimers Dement. 19, 1913\u20131924 (2023).","journal-title":"Alzheimers Dement."},{"key":"942_CR131","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1002\/alz.12787","volume":"19","author":"A Pichet Binette","year":"2023","unstructured":"Pichet Binette, A. et al. Confounding factors of Alzheimer\u2019s disease plasma biomarkers and their impact on clinical performance. Alzheimers Dement. 19, 1403\u20131414 (2023).","journal-title":"Alzheimers Dement."},{"key":"942_CR132","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1002\/alz.12466","volume":"18","author":"JA Syrjanen","year":"2022","unstructured":"Syrjanen, J. A. et al. Associations of amyloid and neurodegeneration plasma biomarkers with comorbidities. Alzheimers Dement. 18, 1128\u20131140 (2022).","journal-title":"Alzheimers Dement."},{"key":"942_CR133","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1038\/s41591-022-01822-2","volume":"28","author":"MM Mielke","year":"2022","unstructured":"Mielke, M. M. et al. Performance of plasma phosphorylated tau 181 and 217 in the community. Nat. Med. 28, 1398\u20131405 (2022).","journal-title":"Nat. Med."},{"key":"942_CR134","doi-asserted-by":"publisher","DOI":"10.1038\/srep20709","volume":"6","author":"D Van Westen","year":"2016","unstructured":"Van Westen, D. et al. Cerebral white matter lesions \u2014 associations with A\u03b2 isoforms and amyloid PET. Sci. Rep. 6, 20709 (2016).","journal-title":"Sci. Rep."},{"key":"942_CR135","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1001\/jamaneurol.2023.0199","volume":"80","author":"S Janelidze","year":"2023","unstructured":"Janelidze, S., Barth\u00e9lemy, N. R., He, Y., Bateman, R. J. & Hansson, O. Mitigating the associations of kidney dysfunction with blood biomarkers of Alzheimer disease by using phosphorylated tau to total tau ratios. JAMA Neurol. 80, 516\u2013522 (2023).","journal-title":"JAMA Neurol."},{"key":"942_CR136","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1212\/CON.0000000000001083","volume":"28","author":"SE Schindler","year":"2022","unstructured":"Schindler, S. E. Fluid biomarkers in dementia diagnosis. Contin. Lifelong Learn. Neurol. 28, 822\u2013833 (2022).","journal-title":"Contin. Lifelong Learn. Neurol."},{"key":"942_CR137","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1002\/alz.12510","volume":"18","author":"IMW Verberk","year":"2022","unstructured":"Verberk, I. M. W. et al. Characterization of pre-analytical sample handling effects on a panel of Alzheimer\u2019s disease-related blood-based biomarkers: results from the Standardization of Alzheimer\u2019s Blood Biomarkers (SABB) working group. Alzheimers Dement. 18, 1484\u20131497 (2022).","journal-title":"Alzheimers Dement."},{"key":"942_CR138","volume":"12","author":"O Hansson","year":"2020","unstructured":"Hansson, O. et al. Pre-analytical protocol for measuring Alzheimer\u2019s disease biomarkers in fresh CSF. Alzheimers Dement. 12, e12137 (2020).","journal-title":"Alzheimers Dement."},{"key":"942_CR139","doi-asserted-by":"publisher","first-page":"4967","DOI":"10.1002\/alz.13026","volume":"19","author":"J Therriault","year":"2023","unstructured":"Therriault, J. et al. Equivalence of plasma p-tau217 with cerebrospinal fluid in the diagnosis of Alzheimer\u2019s disease. Alzheimers Dement. 19, 4967\u20134977 (2023).","journal-title":"Alzheimers Dement."},{"key":"942_CR140","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1038\/s41582-022-00665-2","volume":"18","author":"TK Karikari","year":"2022","unstructured":"Karikari, T. K. et al. Blood phospho-tau in Alzheimer disease: analysis, interpretation, and clinical utility. Nat. Rev. Neurol. 18, 400\u2013418 (2022).","journal-title":"Nat. Rev. Neurol."},{"key":"942_CR141","doi-asserted-by":"publisher","unstructured":"Ashton, N. J. et al. Diagnostic accuracy of a plasma phosphorylated tau 217 immunoassay for Alzheimer disease pathology. JAMA Neurol. e235319, https:\/\/doi.org\/10.1001\/jamaneurol.2023.5319 (2024).","DOI":"10.1001\/jamaneurol.2023.5319"},{"key":"942_CR142","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1186\/s13195-023-01302-w","volume":"15","author":"NS Mundada","year":"2023","unstructured":"Mundada, N. S. et al. Head-to-head comparison between plasma p-tau217 and flortaucipir-PET in amyloid-positive patients with cognitive impairment. Alzheimers Res. Ther. 15, 157 (2023).","journal-title":"Alzheimers Res. Ther."},{"key":"942_CR143","doi-asserted-by":"publisher","first-page":"437","DOI":"10.2967\/jnumed.122.264279","volume":"64","author":"EM Coomans","year":"2023","unstructured":"Coomans, E. M. et al. A head-to-head comparison between plasma ptau181 and tau PET along the Alzheimer\u2019s disease continuum. J. Nucl. Med. 64, 437\u2013443 (2023).","journal-title":"J. Nucl. Med."},{"key":"942_CR144","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1212\/WNL.34.7.939","volume":"34","author":"G McKhann","year":"1984","unstructured":"McKhann, G., Drachman, D., Folstein, M. & Katzman, R. Clinical diagnosis of Alzheimer\u2019s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer\u2019s Disease. Neurology 34, 939\u2013944 (1984).","journal-title":"Neurology"},{"key":"942_CR145","doi-asserted-by":"publisher","first-page":"2636","DOI":"10.1093\/brain\/awm213","volume":"130","author":"S Alladi","year":"2007","unstructured":"Alladi, S. et al. Focal cortical presentations of Alzheimer\u2019s disease. Brain 130, 2636\u20132645 (2007).","journal-title":"Brain"},{"key":"942_CR146","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/S1474-4422(20)30440-3","volume":"20","author":"J Graff-Radford","year":"2021","unstructured":"Graff-Radford, J. et al. New insights into atypical Alzheimer\u2019s disease in the era of biomarkers. Lancet Neurol. 20, 222\u2013234 (2021).","journal-title":"Lancet Neurol."},{"key":"942_CR147","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1016\/S1474-4422(11)70156-9","volume":"10","author":"ME Murray","year":"2011","unstructured":"Murray, M. E. et al. Neuropathologically defined subtypes of Alzheimer\u2019s disease with distinct clinical characteristics: a retrospective study. Lancet Neurol. 10, 785\u2013796 (2011).","journal-title":"Lancet Neurol."},{"key":"942_CR148","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1093\/brain\/aww027","volume":"139","author":"R Ossenkoppele","year":"2016","unstructured":"Ossenkoppele, R. et al. Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer\u2019s disease. Brain 139, 1551\u20131567 (2016).","journal-title":"Brain"},{"key":"942_CR149","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1001\/jamaneurol.2016.5755","volume":"74","author":"C Xia","year":"2017","unstructured":"Xia, C. et al. Association of in vivo [18F]AV-1451 tau PET imaging results with cortical atrophy and symptoms in typical and atypical Alzheimer disease. JAMA Neurol. 74, 427\u2013436 (2017).","journal-title":"JAMA Neurol."},{"key":"942_CR150","doi-asserted-by":"publisher","first-page":"fcaa068","DOI":"10.1093\/braincomms\/fcaa068","volume":"2","author":"RA Townley","year":"2020","unstructured":"Townley, R. A. et al. Progressive dysexecutive syndrome due to Alzheimer\u2019s disease: a description of 55 cases and comparison to other phenotypes. Brain Commun. 2, fcaa068 (2020).","journal-title":"Brain Commun."},{"key":"942_CR151","first-page":"e81","volume":"96","author":"J Therriault","year":"2020","unstructured":"Therriault, J. et al. Topographical distribution of amyloid-\u03b2, tau and atrophy in behavioral\/dysexecutive AD patients. Neurology 96, e81\u2013e92 (2020).","journal-title":"Neurology"},{"key":"942_CR152","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1002\/hbm.23874","volume":"39","author":"JS Phillips","year":"2018","unstructured":"Phillips, J. S. et al. Tau PET imaging predicts cognition in atypical variants of Alzheimer\u2019s disease. Hum. Brain Mapp. 39, 691\u2013708 (2018).","journal-title":"Hum. Brain Mapp."},{"key":"942_CR153","doi-asserted-by":"publisher","first-page":"eabc8693","DOI":"10.1126\/scitranslmed.abc8693","volume":"14","author":"J Therriault","year":"2022","unstructured":"Therriault, J. et al. Intrinsic connectivity of the human brain provides scaffold for tau aggregation in clinical variants of Alzheimer\u2019s disease. Sci. Transl. Med. 14, eabc8693 (2022).","journal-title":"Sci. Transl. Med."},{"key":"942_CR154","doi-asserted-by":"publisher","first-page":"7026","DOI":"10.1093\/cercor\/bhad017","volume":"33","author":"N Corriveau-Lecavalier","year":"2023","unstructured":"Corriveau-Lecavalier, N. et al. Deciphering the clinico-radiological heterogeneity of dysexecutive Alzheimer\u2019s disease. Cereb. Cortex 33, 7026\u20137043 (2023).","journal-title":"Cereb. Cortex"},{"key":"942_CR155","doi-asserted-by":"crossref","first-page":"e650","DOI":"10.1212\/WNL.0000000000011270","volume":"96","author":"R La Joie","year":"2021","unstructured":"La Joie, R. et al. Association of APOE4 and clinical variability in Alzheimer disease with the pattern of tau- and amyloid-PET. Neurology 96, e650\u2013e661 (2021).","journal-title":"Neurology"},{"key":"942_CR156","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1007\/s00401-019-02036-6","volume":"138","author":"C Petersen","year":"2019","unstructured":"Petersen, C. et al. Alzheimer\u2019s disease clinical variants show distinct regional patterns of neurofibrillary tangle accumulation. Acta Neuropathol. 138, 597\u2013612 (2019).","journal-title":"Acta Neuropathol."},{"key":"942_CR157","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1038\/s41591-021-01309-6","volume":"27","author":"JW Vogel","year":"2021","unstructured":"Vogel, J. W. et al. Four distinct trajectories of tau deposition identified in Alzheimer\u2019s disease. Nat. Med. 27, 871\u2013881 (2021).","journal-title":"Nat. Med."},{"key":"942_CR158","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1001\/jamaneurol.2022.0676","volume":"79","author":"CB Young","year":"2022","unstructured":"Young, C. B. et al. Divergent cortical tau positron emission tomography patterns among patients with preclinical Alzheimer disease. JAMA Neurol. 79, 592\u2013603 (2022).","journal-title":"JAMA Neurol."},{"key":"942_CR159","doi-asserted-by":"publisher","first-page":"3776","DOI":"10.1093\/brain\/awaa325","volume":"143","author":"BM Tijms","year":"2020","unstructured":"Tijms, B. M. et al. Pathophysiological subtypes of Alzheimer\u2019s disease based on cerebrospinal fluid proteomics. Brain 143, 3776\u20133792 (2020).","journal-title":"Brain"},{"key":"942_CR160","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2212948","volume":"388","author":"CH van Dyck","year":"2023","unstructured":"van Dyck, C. H. et al. Lecanemab in early Alzheimer\u2019s disease. N. Engl. J. Med. 388, 9\u201321 (2023).","journal-title":"N. Engl. J. Med."},{"key":"942_CR161","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1159\/000511506","volume":"3","author":"A Tian Hui Kwan","year":"2020","unstructured":"Tian Hui Kwan, A., Arfaie, S., Therriault, J., Rosa-Neto, P. & Gauthier, S. Lessons learnt from the second generation of anti-amyloid monoclonal antibodies clinical trials. Dement. Geriatr. Cogn. Disord. 3, 334\u2013348 (2020).","journal-title":"Dement. Geriatr. Cogn. Disord."},{"key":"942_CR162","first-page":"197","volume":"9","author":"S Budd Haeberlein","year":"2022","unstructured":"Budd Haeberlein, S. et al. Two randomized phase 3 studies of aducanumab in early Alzheimer\u2019s disease. J. Prev. Alzheimers Dis. 9, 197\u2013210 (2022).","journal-title":"J. Prev. Alzheimers Dis."},{"key":"942_CR163","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1001\/jamaneurol.2019.4421","volume":"77","author":"J Therriault","year":"2020","unstructured":"Therriault, J. et al. Association of apolipoprotein e \u03f54 with medial temporal tau independent of amyloid-\u03b2. JAMA Neurol. 77, 470\u2013479 (2020).","journal-title":"JAMA Neurol."},{"key":"942_CR164","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/s00401-022-02433-4","volume":"144","author":"ED Plowey","year":"2022","unstructured":"Plowey, E. D. et al. Alzheimer disease neuropathology in a patient previously treated with aducanumab. Acta Neuropathol. 144, 143\u2013153 (2022).","journal-title":"Acta Neuropathol."},{"key":"942_CR165","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1002\/alz.12748","volume":"19","author":"MS Rafii","year":"2023","unstructured":"Rafii, M. S. et al. The AHEAD 3-45 study: design of a prevention trial for Alzheimer\u2019s disease. Alzheimers Dement. 19, 1227\u20131233 (2023).","journal-title":"Alzheimers Dement."},{"key":"942_CR166","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.jalz.2016.07.005","volume":"13","author":"RJ Bateman","year":"2017","unstructured":"Bateman, R. J. et al. The DIAN-TU Next Generation Alzheimer\u2019s prevention trial: adaptive design and disease progression model. Alzheimers Dement. 13, 8\u201319 (2017).","journal-title":"Alzheimers Dement."},{"key":"942_CR167","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1056\/NEJMoa2305032","volume":"389","author":"R Sperling","year":"2023","unstructured":"Sperling, R. et al. Trial of solanezumab in preclinical Alzheimer\u2019s disease. N. Engl. J. Med. 389, 1096\u20131107 (2023).","journal-title":"N. Engl. J. Med."},{"key":"942_CR168","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1001\/jamaneurol.2021.4654","volume":"79","author":"A Leuzy","year":"2022","unstructured":"Leuzy, A. et al. Biomarker-based prediction of longitudinal tau positron emission tomography in Alzheimer disease. JAMA Neurol. 79, 149\u2013158 (2022).","journal-title":"JAMA Neurol."},{"key":"942_CR169","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1001\/jamaneurol.2019.1424","volume":"76","author":"BJ Hanseeuw","year":"2019","unstructured":"Hanseeuw, B. J. et al. Association of amyloid and tau with cognition in preclinical Alzheimer disease: a longitudinal study. JAMA Neurol. 76, 915\u2013924 (2019).","journal-title":"JAMA Neurol."},{"key":"942_CR170","doi-asserted-by":"publisher","first-page":"fcac325","DOI":"10.1093\/braincomms\/fcac325","volume":"5","author":"ATH Kwan","year":"2023","unstructured":"Kwan, A. T. H. et al. Medial temporal tau predicts memory decline in cognitively unimpaired elderly. Brain Commun. 5, fcac325 (2023).","journal-title":"Brain Commun."},{"key":"942_CR171","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1093\/brain\/awac329","volume":"146","author":"C Groot","year":"2023","unstructured":"Groot, C. et al. Phospho-tau with subthreshold tau-PET predicts increased tau accumulation rates in amyloid-positive individuals. Brain 146, 1580\u20131591 (2023).","journal-title":"Brain"},{"key":"942_CR172","doi-asserted-by":"publisher","first-page":"fcab136","DOI":"10.1093\/braincomms\/fcab136","volume":"3","author":"J Therriault","year":"2021","unstructured":"Therriault, J. et al. Association of plasma P-tau181 with memory decline in non-demented adults. Brain Commun. 3, fcab136 (2021).","journal-title":"Brain Commun."},{"key":"942_CR173","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1038\/s41591-021-01348-z","volume":"27","author":"S Palmqvist","year":"2021","unstructured":"Palmqvist, S. et al. Prediction of future Alzheimer\u2019s disease dementia using plasma phospho-tau combined with other accessible measures. Nat. Med. 27, 1034\u20131042 (2021).","journal-title":"Nat. Med."},{"key":"942_CR174","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1001\/jamaneurol.2022.5272","volume":"80","author":"N Mattsson-Carlgren","year":"2023","unstructured":"Mattsson-Carlgren, N. et al. Prediction of longitudinal cognitive decline in preclinical Alzheimer disease using plasma biomarkers. JAMA Neurol. 80, 360\u2013369 (2023).","journal-title":"JAMA Neurol."},{"key":"942_CR175","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1001\/jama.1994.03520020048013","volume":"272","author":"D Moher","year":"1994","unstructured":"Moher, D., Wells, G. A. & Dulberg, C. S. Statistical power, sample size, and their reporting in randomized controlled trials. JAMA 272, 122\u2013124 (1994).","journal-title":"JAMA"},{"key":"942_CR176","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1093\/brain\/awy059","volume":"141","author":"CR Jack","year":"2018","unstructured":"Jack, C. R. et al. Longitudinal tau PET in ageing and Alzheimer\u2019s disease. Brain 141, 1517\u20131528 (2018).","journal-title":"Brain"},{"key":"942_CR177","doi-asserted-by":"publisher","first-page":"3517","DOI":"10.1093\/brain\/awab248","volume":"144","author":"TA Pascoal","year":"2021","unstructured":"Pascoal, T. A. et al. Longitudinal 18F-MK-6240 tau tangles accumulation follows Braak stages. Brain 144, 3517\u20133528 (2021).","journal-title":"Brain"},{"key":"942_CR178","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1002\/ana.25406","volume":"85","author":"TM Harrison","year":"2019","unstructured":"Harrison, T. M. et al. Longitudinal tau accumulation and atrophy in aging and Alzheimer disease. Ann. Neurol. 85, 229\u2013240 (2019).","journal-title":"Ann. Neurol."},{"key":"942_CR179","doi-asserted-by":"publisher","first-page":"eabd1327","DOI":"10.1126\/sciadv.abd1327","volume":"6","author":"N Franzmeier","year":"2020","unstructured":"Franzmeier, N. et al. Patient-centered connectivity-based prediction of tau pathology spread in Alzheimer\u2019s disease. Sci. Adv. 6, eabd1327 (2020).","journal-title":"Sci. Adv."},{"key":"942_CR180","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1111\/j.1750-3639.2008.00147.x","volume":"18","author":"I Alafuzoff","year":"2008","unstructured":"Alafuzoff, I. et al. Staging of neurofibrillary pathology in Alzheimer\u2019s disease: a study of the BrainNet Europe consortium. Brain Pathol. 18, 484\u2013496 (2008).","journal-title":"Brain Pathol."},{"key":"942_CR181","doi-asserted-by":"publisher","first-page":"fcac017","DOI":"10.1093\/braincomms\/fcac017","volume":"4","author":"CR Jack","year":"2022","unstructured":"Jack, C. R. et al. Long-term associations between amyloid positron emission tomography, sex, apolipoprotein E and incident dementia and mortality among individuals without dementia: hazard ratios and absolute risk. Brain Commun. 4, fcac017 (2022).","journal-title":"Brain Commun."},{"key":"942_CR182","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2023.09.003","author":"V Ourry","year":"2023","unstructured":"Ourry, V. et al. How do modifiable risk factors affect Alzheimer\u2019s disease pathology or mitigate its effect on clinical symptom expression? Biol. Psychiatry https:\/\/doi.org\/10.1016\/j.biopsych.2023.09.003 (2023).","journal-title":"Biol. Psychiatry"},{"key":"942_CR183","doi-asserted-by":"publisher","first-page":"3719","DOI":"10.1093\/brain\/awad100","volume":"146","author":"DI Bocancea","year":"2023","unstructured":"Bocancea, D. I. et al. Determinants of cognitive and brain resilience to tau pathology: a longitudinal analysis. Brain 146, 3719\u20133734 (2023).","journal-title":"Brain"},{"key":"942_CR184","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1001\/jamaneurol.2019.5154","volume":"77","author":"R Ossenkoppele","year":"2020","unstructured":"Ossenkoppele, R. et al. Assessment of demographic, genetic, and imaging variables associated with brain resilience and cognitive resilience to pathological tau in patients with Alzheimer disease. JAMA Neurol. 77, 632\u2013642 (2020).","journal-title":"JAMA Neurol."},{"key":"942_CR185","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1186\/s13024-022-00586-0","volume":"17","author":"J Gobom","year":"2022","unstructured":"Gobom, J. et al. Antibody-free measurement of cerebrospinal fluid tau phosphorylation across the Alzheimer\u2019s disease continuum. Mol. Neurodegener. 17, 81 (2022).","journal-title":"Mol. Neurodegener."},{"key":"942_CR186","doi-asserted-by":"publisher","first-page":"E245","DOI":"10.1212\/WNL.0000000000200358","volume":"99","author":"SE Schindler","year":"2022","unstructured":"Schindler, S. E. et al. Effect of race on prediction of brain amyloidosis by plasma A\u03b242\/A\u03b240, phosphorylated tau, and neurofilament light. Neurology 99, E245\u2013E257 (2022).","journal-title":"Neurology"},{"key":"942_CR187","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1038\/s41591-022-01875-3","volume":"28","author":"SE Schindler","year":"2022","unstructured":"Schindler, S. E. & Karikari, T. K. Comorbidities confound Alzheimer\u2019s blood tests. Nat. Med. 28, 1349\u20131351 (2022).","journal-title":"Nat. Med."}],"container-title":["Nature Reviews Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41582-024-00942-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41582-024-00942-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41582-024-00942-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,4]],"date-time":"2024-04-04T13:05:04Z","timestamp":1712235904000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41582-024-00942-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,1]]},"references-count":187,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["942"],"URL":"https:\/\/doi.org\/10.1038\/s41582-024-00942-2","relation":{},"ISSN":["1759-4758","1759-4766"],"issn-type":[{"value":"1759-4758","type":"print"},{"value":"1759-4766","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,1]]},"assertion":[{"value":"5 February 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 March 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"J.T. has received consultancy fees from the Neurotorium educational platform outside the scope of the present work. L.A. has received grants from the National Institute on Aging, the Alzheimer\u2019s Association, AVID Radiopharmaceuticals, Life Molecular Imaging, and Roche Diagnostics and personal fees from Eli Lilly, Biogen, Two Labs, IQVIA, Genentech, Siemens, Corium, GE Healthcare, Eisai, Roche Diagnostics, Alnylam, the Alzheimer\u2019s Association, and from the FDA outside the submitted work. C.T. reports non-financial support from Quanterix during the conduct of the study, has a patent pending for glial fibrillary acidic protein as a biomarker, serves as an editorial board member of <i>Alzheimer\u2019s Research and Therapy<\/i>, <i>Medidact Neurologie<\/i> (Springer), and <i>Neurology: Neuroimmunology & Neuroinflammation<\/i>, serves as an editor of the Neuromethods book series (Springer), and reports grants from Roche Diagnostics, non-financial support from ADx Neurosciences and Eli Lilly, and compensation from AC Immune, Axon Neurosciences, Biogen, Brainstorm Cell Therapeutics, Celgene, Denali Therapeutics, EIP Pharma, Eisai, PeopleBio, Toyama Pharmaceutical Association and Vivoryon Therapeutics outside the submitted work. G.D.R. has received grants from the American College of Radiology, Avid Radiopharmaceuticals, Life Molecular Imaging (formerly Piramal Imaging) and GE Healthcare during the conduct of the study, personal fees from Alector, Eli Lilly, Merck, and the Johnson & Johnson Data and Safety Monitoring Board and grants from Genentech, the NIH, the Alzheimer\u2019s Association, and Rainwater Charitable Foundation outside the submitted work, and is an Associate Editor for <i>JAMA Neurology<\/i>. R.J.B. declares research funding from Avid Radiopharmaceuticals, Janssen, Roche\/Genentech, Eli Lilly, Eisai, Biogen, AbbVie, Bristol Myers Squibb and Novartis, equity ownership interest in C2N Diagnostics and income from C2N Diagnostics for serving on the scientific advisory board, serves on the Roche gantenerumab steering committee as an unpaid member, has income based on technology (blood plasma assay and methods of diagnosing Alzheimer disease with phosphorylation changes) licensed by Washington University to C2N Diagnostics, and also declares involvement with the Alzheimer\u2019s Association, Duke Margolis Alzheimer\u2019s, BrightFocus Foundation and Tau Consortium Investigators\u2019 Meeting. H.Z. has served on scientific advisory boards and\/or as a consultant for Abbvie, Acumen, Alector, Alzinova, ALZPath, Annexon, Apellis, Artery Therapeutics, AZTherapies, Cognito Therapeutics, CogRx, Denali, Eisai, Nervgen, Novo Nordisk, Optoceutics, Passage Bio, Pinteon Therapeutics, Prothena, Red Abbey Labs, reMYND, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics, and Wave, has given lectures in symposia sponsored by Cellectricon, Fujirebio, Alzecure, Biogen and Roche, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (outside the submitted work). P.S. is a full-time employee of EQT Life Sciences (formerly LSP) and Professor Emeritus at Amsterdam University Medical Centers. He has received consultancy fees (paid to the university) from Alzheon, Brainstorm Cell and Green Valley. Within his university affiliation, he was the global Principal Investigator of a phase Ib study for AC Immune, a phase IIb study for FUJI-film\/Toyama and a phase II study for UCB. He is past chair of the European Union steering committee of the Vivoryon phase IIb programme and a phase IIb study for Novartis Cardiology, and is currently co-chair of a phase III study for Novo Nordisk. K.B. has served as a consultant and on advisory boards for Acumen, ALZPath, BioArctic, Biogen, Eisai, Julius Clinical, Lilly, Novartis, Ono Pharma, Prothena, Roche Diagnostics and Siemens Healthineers, has served on data monitoring committees for Julius Clinical and Novartis, has given lectures, produced educational materials and participated in educational programmes for Biogen, Eisai and Roche Diagnostics, and is a co-founder of BBS, which is part of the GU Ventures Incubator Program, outside the work presented in this paper. R.S. reports grant support from the NIH, Eli Lilly, the Alzheimer\u2019s Association, GHR Foundation, Fidelity, and Gates Ventures, non-financial support from CogState and Mount Sinai, grants and personal fees from Janssen, and personal fees from AC Immune, Biogen, Neurocentria, Eisai, Roche, Takeda and Novartis. O.H. has acquired research support (for the institution) from ADx, AVID Radiopharmaceuticals, Biogen, Eli Lilly, Eisai, Fujirebio, GE Healthcare, Pfizer and Roche. In the past 2 years, he has received consultancy or speaker fees from AC Immune, Amylyx, Alzpath, BioArctic, Biogen, Cerveau, Eisai, Eli Lilly, Fujirebio, Merck, Novartis, Novo Nordisk, Roche, Sanofi and Siemens. P.R.-N. has served on scientific advisory boards and\/or as a consultant for Roche, Novo Nordisk, Eisai and Cerveau Technologies. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}